RESEARCH MONOGRAPH · KDC-MN-122

Methylene Blue

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

71/100

Alternative electron carrier with real biology at low doses. Probably the most legitimately interesting old dye in pharmacology

Methylene blue is one of those molecules that keeps quietly turning out to be more interesting than it has any right to be. Synthesized in 1876 by Heinrich Caro, originally a textile dye, then the first synthetic drug (used by Ehrlich for malaria), then a methemoglobinemia treatment, then a putative neuroprotectant. The molecule has been in continuous medical use for over 130 years and the mechanism story keeps getting deeper.

At low doses (microMolar plasma concentrations, which oral doses in the very-low-mg range produce) methylene blue acts as an alternative electron carrier, bypassing parts of the respiratory chain by accepting electrons from NADH and donating them to cytochrome c or oxygen. The Atamna group and Wrubel/Sheth/Riha and others have shown this can support ATP production in conditions where Complex I or III is compromised. There's also reversible MAO-A inhibition (significant for serotonin syndrome risk in combination with serotonergic drugs), guanylate cyclase inhibition (relevant for nitric-oxide-mediated effects), tau aggregation inhibition (the Wischik group's work on TauRx, which led to LMTM/hydromethylthionine for Alzheimer's trials), and prion-like aggregation inhibition more broadly.

The dose-response is the entire story. At low doses methylene blue is a redox modulator and electron shuttle. At higher doses it becomes a redox-cycling pro-oxidant and the pharmacology flips substantially. The threshold is steep enough that the difference between research-interesting low-dose and overtly-problematic higher-dose is meaningful. Most of the supplement-market positioning is uninformed about this.

The cognitive trial base in humans is small but unusually consistent in direction. Acute low-dose methylene blue has shown signal on working memory and attention in healthy adults (Rodriguez 2016 fMRI study at UT-Austin, plus a few small clinical trials). The TauRx Alzheimer's program with hydromethylthionine (the reduced form, more bioavailable) had mixed phase 3 results that the company contested heavily.

What we like: real, multi-target pharmacology with mitochondrial and neurological mechanisms that have at least partial empirical support. One of the few small molecules with this kind of historical track record and ongoing serious research interest.

What we dont like is the supplement-market dose disaster. People take far more methylene blue than the research literature suggests is interesting, and the contraindications with serotonergic medications are real and can produce severe serotonin syndrome.

Sourcing: USP-grade methylene blue (medical-grade, low heavy-metal content) is essential. Textile-dye-grade or aquarium-grade methylene blue contains contaminants you don't want. HPLC 99%+ purity verified material from research suppliers is the legitimate route.

One of the more interesting compounds in the older pharmacology literature, dose-sensitive in important ways.

Evidence: 60
Mechanism: 78
Reliability: 65
Safety: 65
Sourcing: 65
Value: 80
Signal: 78
Staying power: 75

Plain-language summary Intrigue 75 / 100

Methylene blue is a phenothiazine dye used historically for malaria, methemoglobinemia, and septic shock. At low doses it serves as an alternative electron donor in mitochondria, supporting energy production when normal pathways are impaired. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phenothiazine dye / electron donor

A phenothiazine dye used historically as an antimalarial and methemoglobinemia treatment, with mitochondrial electron-cycling activity at low doses for cognitive applications.

Abstract

Methylene blue (methylthioninium chloride; CAS 61-73-4; molecular formula C16H18ClN3S; molecular weight 319.85) is a phenothiazine dye with the longest pharmaceutical history of any synthetic compound (first synthesized 1876). The compound is FDA-approved for methemoglobinemia and has historical use as an antimalarial. Low-dose methylene blue has been studied for cognitive enhancement, traumatic brain injury, and Alzheimer disease, based on the compound's mitochondrial electron-cycling activity (donates electrons to Complex III, bypassing dysfunctional Complex I/II). Pharmacology is complex and dose-dependent; higher exposures produce MAO inhibition and serotonin syndrome risk. Reported research dose ranges in the literature for low-dose cognitive studies are around 5 to 20 mg. The compound stains tissues and excreta blue, which is cosmetically obvious but harmless.

Mechanism of action

Mitochondrial electron donor (Complex III); bypasses Complex I/II. MAO inhibition at higher doses.

Reported research dose ranges

Reported research dose ranges in the literature for low-dose cognitive studies are around 5 to 20 mg.

References

Rojas JC, et al. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-122

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Methylene Blue

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs